hen Novartis (NVS) announced an eye-popping $475,000 price for its new gene-therapy cancer treatment last month, the company also touted a money-back guarantee: if a patient fails to respond in the first month, there will be no charge. The deal generated praise, but also questions about the extent to which payers and patients will benefit. Several Democratic lawmakers are now seeking answers.

Unfortunately, details have not been released, which raises some key issues. For instance, it remains unclear how patient responses to the drug — which is called Kymriah and was approved to treat children with an aggressive form of leukemia — will be measured. Moreover, a 30-day cutoff can easily work in the company’s favor, since a short-term benefit is more typical among cancer patients.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy